Navigation Links
U Alberta finds weakness in armor of killer hospital bacteria
Date:6/8/2012

There's new hope for development of an antibiotic that can put down a lethal bacteria or superbug linked to the deaths of hundreds of hospital patients around the world.

Researchers from the University of Alberta-based Alberta Glycomics Centre found a chink in the molecular armour of the pathogen Acinetobacter baumannii. The bacteria first appeared in the 1970's and in the last decade it developed a resistance to most antibiotics.

U of A microbiologist Mario Feldman identified a mechanism that allows Acinetobacter baumannii to cover its surface with molecules knows as glycoproteins.

Feldman and his team then discovered that if the superbug cannot produce glycoproteins they become less virulent and less capable of forming biofilms, which protect the bacteria from antibiotics.

Feldman says more work is required to understand how the bacteria produces glycoproteins. The researchers say that will enable future development of drugs to interrupt the production of glycoproteins, reducing the bacteria's ability to shield it from antibiotics.

Acinetobacter baumannii is a particularly insidious and contagious pathogenic bacteria that has plagued hospitals around the world. It spreads from one person to another by physical contact. The bacteria can live on hard surfaces for several days and can cling to hospital equipment like catheter tubes and inhalers. Acinetobacter baumannii is also spread by coughing and sneezing.

Hospital patients whose immune systems are already worn down are the most susceptible to Acinetobacter baumannii. It infects wounds and can spread to the lungs, blood and brain.

Feldman is a principal investigator for the Alberta Glycomics Centre at the U of A. He was assisted by U of A graduate students Jeremy Iwashkiw and Brent Weber along with research colleagues in Ottawa, Austria and Australia. Their work was published June 7 in the journal PLoS Pathogens.


'/>"/>

Contact: Brian Murphy
brian.murphy@ualberta.ca
780-492-6041
University of Alberta
Source:Eurekalert

Related biology technology :

1. Study finds chronic abnormal brain blood flow in Gulf War veterans
2. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
3. Study In Prenatal Diagnosis Finds Sequenom CMMs MaterniT21™ PLUS Lab-developed Test Accurately Detects Fetal Trisomies In Pregnant Women Carrying Twins Or Triplets
4. Armored caterpillar could inspire new body armor
5. NTU scientists invent superbug killers
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. Antelope Valley Hospital Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities
8. What Hospitals Must Do to Thrive -- Not Just Survive -- on Medicare Margins
9. Meaningful Use Stage Two: The Advisory Board Company Helps Hospitals Set Strategy
10. Biotech Firm Spun Off from Childrens Hospital Raises $7 Million to Advance Magnetic-Based Vascular Treatment
11. Narayana Hrudayalaya Hospitals Teams With Ascension Health Alliance to Build Health City at Grand Cayman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... medical technologies, services and solutions to the healthcare market. The company's primary focus ... distribution, manufacturing, sales and marketing strategies that are necessary to help companies efficiently ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
Breaking Biology Technology:
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):